Comparing the current results to its competitors, Nextcure Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 16.46 %, recorded in the same quarter.
Nextcure Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes larger biopharmaceutical, biotechnology, and therapeutics firms, as well as smaller or early-stage companies, universities, and research institutions developing cancer therapeutics. In the CDH6-targeted program space, SIM0505 competes with raludotatug deruxtecan (R-DXd), co-developed by Merck & Co. and Daiichi Sankyo, OnCusp Therapeutics' CUSP06, and Hansoh Pharma’s HS-20124. In the ovarian cancer sector, competitors include AbbVie’s marketed product Elahere, Genmab’s clinical candidate rinatabart sesutecan (Rina-S), and the clinical candidate TUB-040 targeting NaPi2b. The company's competitive position relies on differentiating SIM0505 through its proprietary topoisomerase 1 inhibitor payload, safety profile, and efficacy across tumor types.
November 19, 2024
Osteogenesis imperfecta (OI), characterized by brittle bones and high susceptibility to fractures, has long posed significant challenges in medical management. Recent advancements in therapeutic strategies, particularly involving the treatment of Siglec-15, offer promising new avenues for enhancing bone quality and strength in individuals suffering from moderate-to-severe forms of this condition. Preclinical studies have demonstrated that anti-Siglec-15 treatment facilitates the generation of high-quality bone with superior mechanical properties in murine models. In these studies, mice with moderate-to-severe OI exhibited notable improvements in bone density and mechanical resilience following treatment. The...
March 21, 2024
NextCure, Inc., a clinical-stage biopharmaceutical company, recently provided a comprehensive business update along with its full-year financial results for 2023. The company, committed to discovering and developing novel, first-in-class immunomedicines for the treatment of cancer and immune-related diseases, has also published significant non-clinical data demonstrating the prevention of bone loss and preservation of bone strength in animal models of severe immobilization caused by acute spinal cord injury.Business Update and Financial Results:NextCure, Inc. has reported its full-year financial results for 2023. The company expressed its commitment to discovering and developing groundbreaking therapies for ...
Madrigal Pharmaceuticals Inc's business model is focused on developing and commercializing innovative therapeutic solutions for liver diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other metabolic diseases. They aim to provide effective treatments to address unmet medical needs and improve patient outcomes in these areas.
Ligand Pharmaceuticals Inc operates on a business model focused on discovering and acquiring new drugs and technologies to license them to pharmaceutical companies. They generate revenue through licensing fees, milestone payments, and royalties from the sales of their partnered products. Their approach allows them to leverage their expertise and resources while minimizing risk, ultimately leading to long-term value creation for their shareholders.
Durect Corp operates as a specialty pharmaceutical company that develops and commercializes innovative products for the treatment of chronic diseases. Their business model revolves around the research, development, and commercialization of their proprietary drug delivery technologies and therapeutics to address unmet medical needs.
Adagene Inc is a biotechnology company that develops novel antibody therapeutics for cancer treatment by leveraging its proprietary Dynamic Precision Library platform. Their business model involves partnering with pharmaceutical companies for the development and commercialization of their products.
Sources:
Nextcure Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Nextcure Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
